These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28147447)

  • 1. Patient subgroup identification for clinical drug development.
    Huang X; Sun Y; Trow P; Chatterjee S; Chakravartty A; Tian L; Devanarayan V
    Stat Med; 2017 Apr; 36(9):1414-1428. PubMed ID: 28147447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.
    Li W; Chen C; Li X; Beckman RA
    Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tutorial in biostatistics: data-driven subgroup identification and analysis in clinical trials.
    Lipkovich I; Dmitrienko A; B R
    Stat Med; 2017 Jan; 36(1):136-196. PubMed ID: 27488683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiplicity considerations in subgroup analysis.
    Dmitrienko A; Millen B; Lipkovich I
    Stat Med; 2017 Dec; 36(28):4446-4454. PubMed ID: 28762525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity to censored-at-random assumption in the analysis of time-to-event endpoints.
    Lipkovich I; Ratitch B; O'Kelly M
    Pharm Stat; 2016 May; 15(3):216-29. PubMed ID: 26997353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some remaining challenges regarding multiple endpoints in clinical trials.
    Snapinn S
    Stat Med; 2017 Dec; 36(28):4441-4445. PubMed ID: 28664566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial.
    Tanaka S; Matsuyama Y; Ohashi Y
    Stat Med; 2017 Aug; 36(19):2963-2977. PubMed ID: 28485043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables.
    Sozu T; Sugimoto T; Hamasaki T
    Biom J; 2012 Sep; 54(5):716-29. PubMed ID: 22829198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subgroup identification for treatment selection in biomarker adaptive design.
    Lu TP; Chen JJ
    BMC Med Res Methodol; 2015 Dec; 15():105. PubMed ID: 26646831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting analysis time in events-driven clinical trials using accumulating time-to-event surrogate information.
    Wang J; Ke C; Yu Z; Fu L; Dornseif B
    Pharm Stat; 2016 May; 15(3):198-207. PubMed ID: 26689725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Composite and multicomponent end points in clinical trials.
    Sankoh AJ; Li H; D'Agostino RB
    Stat Med; 2017 Dec; 36(28):4437-4440. PubMed ID: 28675919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statistical design for a confirmatory trial with a continuous predictive biomarker: A case study.
    Joshi A; Zhang J; Fang L
    Contemp Clin Trials; 2017 Dec; 63():19-29. PubMed ID: 28522422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weighted analysis of composite endpoints with simultaneous inference for flexible weight constraints.
    Duc AN; Wolbers M
    Stat Med; 2017 Feb; 36(3):442-454. PubMed ID: 27782312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling and prediction of subject accrual and event times in clinical trials: a systematic review.
    Zhang X; Long Q
    Clin Trials; 2012 Dec; 9(6):681-8. PubMed ID: 22674642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.
    Jiang Z; Song Y; Shou Q; Xia J; Wang W
    Trials; 2014 Dec; 15():500. PubMed ID: 25528466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of composite endpoints in clinical trials.
    Sankoh AJ; Li H; D'Agostino RB
    Stat Med; 2014 Nov; 33(27):4709-14. PubMed ID: 24833282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Novel, Value-Based, Digital Endpoints for Clinical Trials: A Structured Approach Toward Fit-for-Purpose Validation.
    Kruizinga MD; Stuurman FE; Exadaktylos V; Doll RJ; Stephenson DT; Groeneveld GJ; Driessen GJA; Cohen AF
    Pharmacol Rev; 2020 Oct; 72(4):899-909. PubMed ID: 32958524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiplicity issues in exploratory subgroup analysis.
    Lipkovich I; Dmitrienko A; Muysers C; Ratitch B
    J Biopharm Stat; 2018; 28(1):63-81. PubMed ID: 29173045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.